Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Bridging the gaps of headache care for underserved populations: Current status of the headache field in Latin America

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of KATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Headache provocation by nitric oxide in men who have never experienced a headache

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Bridging the gaps of headache care for underserved populations: Current status of the headache field in Latin America

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of KATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: This post hoc subgroup analysis evaluated the efficacy and safety of eptinezumab for migraine prevention in patients with migraine and self-reported aura.

METHODS: PROMISE-1 (NCT02559895; episodic migraine) and PROMISE-2 (NCT02974153; chronic migraine) were randomized, double-blind, placebo-controlled trials that evaluated eptinezumab for migraine prevention. In both studies, the primary outcome was the mean change from baseline in monthly migraine days over Weeks 1-12. Patients in this analysis included those who self-reported migraine with aura at screening.

RESULTS: Of patients with episodic migraine, ∼75% reported a history of aura at screening; of patients with chronic migraine, ∼35% reported a history of aura. Changes in monthly migraine days over Weeks 1-12 were -4.0 (100 mg) and -4.2 (300 mg) with eptinezumab versus -3.1 with placebo in patients with episodic migraine with aura, and were -7.1 (100 mg) and -7.6 (300 mg) with eptinezumab versus -6.0 with placebo in patients with chronic migraine with aura. Treatment-emergent adverse events were reported by 56.0% (100 mg), 57.4% (300 mg), and 55.4% (placebo) of patients.

CONCLUSIONS: The preventive migraine efficacy of eptinezumab in patients in the PROMISE studies who self-reported aura was comparable to the overall study populations, demonstrating a similarly favorable safety and tolerability profile.Trial registration: ClinicalTrials.gov Identifiers: NCT02559895 and NCT02974153.

OriginalsprogEngelsk
TidsskriftCephalalgia : an international journal of headache
Vol/bind42
Udgave nummer8
Sider (fra-til)696-704
Antal sider9
ISSN0333-1024
DOI
StatusUdgivet - jul. 2022

ID: 75687480